Libre CGM improves basal‑insulin T2D care
A landmark study released this week reported that Libre CGM technology helped people with type‑2 diabetes on basal insulin improve glucose management — evidence that intermittent CGM or flash systems can change outcomes in non‑intensive insulin regimens. The paper is being cited as a major data point for expanding CGM coverage in T2D. (diabetestimes.co.uk)
The FreeDM2 randomized controlled trial enrolled 303 adults across 24 clinical sites in the U.K. and its results were presented at the 19th ATTD conference in Barcelona (March 11–14, 2026). (abbott.mediaroom.com - attd.kenes.com - ) At the four‑month primary endpoint, Libre users showed a 0.6 percentage‑point greater reduction in HbA1c versus finger‑stick SMBG (p<0.001) and spent roughly 2.5 more hours per day — a 10.4% increase — in the 70–180 mg/dL target range. (abbott.mediaroom.com - ) Study investigators reported the cohort were on basal insulin with concomitant SGLT2 inhibitor or GLP‑1 receptor agonist therapies, and co‑lead investigators Emma G. Wilmot and Lala Leelarathna highlighted that real‑time glucose visibility enabled participant‑led adjustments to diet, basal dosing and activity. (abbott.mediaroom.com - ) A complementary Italian interventional study presented alongside FreeDM2 followed 88 adults on basal insulin for three months using FreeStyle Libre (Flash) monitoring and reported improvements in average glucose, time‑in‑range and patient‑reported quality‑of‑life measures. (abbott.mediaroom.com - clinicaltrials.gov NCT06268808 - ) Abbott is already running a larger UK FreeStyle Libre 3 trial (NCT05944432, sponsor Abbott Diabetes Care) designed to compare CGM versus SMBG over two four‑month phases, with estimated enrollment 470 and a primary completion date listed as March 30, 2026. (clinicaltrials.gov - ) Abbott framed FreeDM2 and the Italian data as strengthening the case for broader CGM reimbursement for people on basal‑only insulin regimens — noting that current coverage in many regions tends to prioritise multiple‑daily‑injection users. (drugdeliverybusiness.com - abbott.mediaroom.com - )
